XML 52 R35.htm IDEA: XBRL DOCUMENT v3.3.1.900
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
2 Months Ended 12 Months Ended
Jan. 12, 2016
shares
Feb. 17, 2016
shares
Dec. 31, 2015
USD ($)
Dec. 31, 2014
USD ($)
Dec. 31, 2013
USD ($)
Advertising costs     $ 792,574 $ 698,871 $ 11,739
Federal insurance limits     $ 250,000    
Number of issued patents     14    
Shelf life of prescription products     24 months    
Related to Research and Development Activities [Member]          
Advance payments - total     $ 1,138,073 1,175,082  
Advance payments - other assets current     1,009,175 711,362  
Advance payments - long term prepaid expense     $ 128,898 $ 463,720  
Subsequent Event- Underwriting Agreement [Member]          
Shares issued in offerings, net of cost, shares | shares 15,151,515 17,424,242      
Minimum [Member]          
Return period of unsalable prescription products     6 months    
Maximum [Member]          
Return period of unsalable prescription products     24 months